Karuna Therapeutics
2023
$14.0B
Why
The organization acquired Karuna Therapeutics for $14.0 billion to secure exclusive rights to KarXT (Cobenfy), a novel muscarinic agonist for the treatment of schizophrenia, marking a decisive and aggressive entry into the highly lucrative neuroscience therapeutic area.
Impact
The acquisition provided the organization with a proven neuroscience platform and a deep pipeline of early-stage assets in schizophrenia and other neurological diseases, positioning the company at the forefront of the next-generation antipsychotic market.
Outcome
Cobenfy was approved by the FDA in late 2024, representing a major breakthrough in neuroscience and a potential blockbuster asset for the organization.